Subscribe to our newsletter.
Instructions for Use
For any missing information or if you require additional details, please do not hesitate to contact us.
FXIII V34L RealFast™ Assay: A Genetic Test for Thrombophilia Risk Assessment
Introduction: The FXIII V34L RealFast™ Assay is a cutting-edge genetic test designed to assess an individual’s risk of thrombophilia. Thrombophilia refers to a condition where the blood has an increased tendency to form abnormal blood clots, which can lead to serious health complications such as deep vein thrombosis (DVT) or pulmonary embolism. This assay focuses on a specific genetic variant within the Factor XIII (F13A) gene, known as V34L, which has been associated with altered clot formation and various cardiovascular conditions.
Understanding Thrombophilia: To comprehend the significance of the FXIII V34L RealFast™ Assay, it’s crucial to understand the role of Factor XIII in blood coagulation. Activated Factor XIII plays a pivotal role in stabilizing the fibrin clot during the final stages of blood coagulation. It achieves this by cross-linking fibrin fibers, thereby enhancing the clot’s stability.
The Genetic Variant: The V34L genetic variant results from a G>T transition in exon 2 of the F13A gene, leading to the substitution of valine (V) with leucine (L) at amino acid position 34 of the Factor XIII subunit A. This seemingly small change has significant implications for clot formation and thrombophilia risk.
Protective Effects: Studies have shown that individuals carrying the V34L variant may experience a protective effect against certain thrombotic events. Specifically, this variant has been associated with a decreased risk of arterial and venous thrombosis. It is believed that the altered clot structure, characterized by thinner fibers and smaller pores, contributes to this protective effect.
Contradictory Findings: While the V34L variant offers protection against some thrombotic conditions, it’s important to note that it has also been associated with an increased risk of recurrent pregnancy loss in women who carry additional thrombophilic mutations. This highlights the complexity of genetic risk factors and their interactions within the context of thrombophilia.
Conclusion: The FXIII V34L RealFast™ Assay provides valuable insights into an individual’s genetic predisposition to thrombophilia. By identifying carriers of the V34L variant, healthcare providers can offer personalized risk assessments and interventions to mitigate the potential for thrombotic events. Understanding the genetic basis of thrombophilia is a crucial step in improving patient outcomes and enhancing the field of cardiovascular medicine.